EMA Application withdrawn: Aripiprazole Mylan (aripiprazole) — Mylan S.A.S.

View source ↗

Summary

The EMA withdrew the application for Aripiprazole Mylan (aripiprazole) by Mylan S.A.S. for schizophrenia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Aripiprazole Mylan (aripiprazole)

Snippet

Status: Application withdrawn. Therapeutic area: Schizophrenia. MAH: Mylan S.A.S.. Decision date: 29/01/2016